Atazanavir/cobicistat (trade name Evotaz) is an antiretroviral medication used to treat and prevent HIV/AIDS. It is a fixed dose combination drug containing 300 mg of atazanavir and 150 mg of cobicistat. Atazanavir is an HIV protease inhibitor and cobicistat blocks the body's metabolism of atazanavir by the enzyme CYP3A prolonging its effectiveness.
|Atazanavir||HIV protease inhibitor|
|Cobicistat||Cytochrome P450 (CYP3A) inhibitor|
- "Evotaz Packing Insert" (PDF).
- "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb.